Literature DB >> 16862542

ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I.

Olivier Leroy1, Claire-Marie Dhaenens, Suzanna Schraen-Maschke, Karim Belarbi, André Delacourte, Athena Andreadis, Bernard Sablonnière, Luc Buée, Nicolas Sergeant, Marie-Laure Caillet-Boudin.   

Abstract

Altered splicing of transcripts, including the insulin receptor (IR) and the cardiac troponin (cTNT), is a key feature of myotonic dystrophy type I (DM1). CELF and MBNL splicing factor members regulate the splicing of those transcripts. We have previously described an alteration of Tau exon 2 splicing in DM1 brain, resulting in the favored exclusion of exon 2. However, the factors required for alternative splicing of Tau exon 2 remain undetermined. Here we report a decreased expression of CELF family member and MBNL transcripts in DM1 brains as assessed by RT-PCR. By using cellular models with a control- or DM1-like splicing pattern of Tau transcripts, we demonstrate that ETR-3 promotes selectively the exclusion of Tau exon 2. These results together with the analysis of Tau exon 6 and IR exon 11 splicing in brain, muscle, and cell models suggest that DM1 splicing alteration of several transcripts involves various factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862542     DOI: 10.1002/jnr.20980

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  22 in total

Review 1.  RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity.

Authors:  Gloria V Echeverria; Thomas A Cooper
Journal:  Brain Res       Date:  2012-02-22       Impact factor: 3.252

2.  Signal- and development-dependent alternative splicing of LEF1 in T cells is controlled by CELF2.

Authors:  Michael J Mallory; Jason Jackson; Brittany Weber; Anthony Chi; Florian Heyd; Kristen W Lynch
Journal:  Mol Cell Biol       Date:  2011-03-28       Impact factor: 4.272

Review 3.  Therapeutics development in myotonic dystrophy type 1.

Authors:  Erin Pennock Foff; Mani S Mahadevan
Journal:  Muscle Nerve       Date:  2011-05-23       Impact factor: 3.217

Review 4.  The role of CELF proteins in neurological disorders.

Authors:  Jean-Marc Gallo; Carl Spickett
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 5.  The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins.

Authors:  Twishasri Dasgupta; Andrea N Ladd
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-08-17       Impact factor: 9.957

6.  Reduced Expression of RNA Binding Protein CELF2, a Putative Tumor Suppressor Gene in Colon Cancer.

Authors:  Satish Ramalingam; Prabhu Ramamoorthy; Dharmalingam Subramaniam; Shrikant Anant
Journal:  Immunogastroenterology       Date:  2012

Review 7.  CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.

Authors:  Andrea N Ladd
Journal:  Mol Cell Neurosci       Date:  2012-12-14       Impact factor: 4.314

8.  CUGBP2 directly interacts with U2 17S snRNP components and promotes U2 snRNA binding to cardiac troponin T pre-mRNA.

Authors:  Young-Hwa Goo; Thomas A Cooper
Journal:  Nucleic Acids Res       Date:  2009-05-14       Impact factor: 16.971

9.  Cognitive impairment in myotonic dystrophy type 1 (DM1): a longitudinal follow-up study.

Authors:  A Modoni; G Silvestri; M Gabriella Vita; D Quaranta; P A Tonali; C Marra
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

Review 10.  Pathogenic RNAs in microsatellite expansion disease.

Authors:  Jihae Shin; Konstantinos Charizanis; Maurice S Swanson
Journal:  Neurosci Lett       Date:  2009-08-04       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.